IL302386A - Methods of reducing tau in human subjects - Google Patents
Methods of reducing tau in human subjectsInfo
- Publication number
- IL302386A IL302386A IL302386A IL30238623A IL302386A IL 302386 A IL302386 A IL 302386A IL 302386 A IL302386 A IL 302386A IL 30238623 A IL30238623 A IL 30238623A IL 302386 A IL302386 A IL 302386A
- Authority
- IL
- Israel
- Prior art keywords
- serum
- tau
- administration
- csf
- days
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105804P | 2020-10-26 | 2020-10-26 | |
| PCT/EP2021/079543 WO2022090158A1 (en) | 2020-10-26 | 2021-10-25 | Methods of reducing tau in human subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302386A true IL302386A (en) | 2023-06-01 |
Family
ID=78402146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302386A IL302386A (en) | 2020-10-26 | 2021-10-25 | Methods of reducing tau in human subjects |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220127345A1 (https=) |
| EP (1) | EP4232155A1 (https=) |
| JP (1) | JP2023546504A (https=) |
| KR (1) | KR20230093499A (https=) |
| CN (1) | CN116916955A (https=) |
| AU (1) | AU2021367878A1 (https=) |
| CA (1) | CA3199806A1 (https=) |
| IL (1) | IL302386A (https=) |
| MX (1) | MX2023004831A (https=) |
| TW (1) | TW202233666A (https=) |
| WO (1) | WO2022090158A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP7379764B1 (ja) | 2022-08-09 | 2023-11-15 | レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 空気分離装置および空気分離方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP6214161B2 (ja) * | 2009-12-21 | 2017-10-18 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN117820467A (zh) * | 2016-12-07 | 2024-04-05 | 基因泰克公司 | 抗tau抗体和使用方法 |
| TWI771389B (zh) * | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| MA53338A (fr) * | 2018-03-05 | 2022-01-05 | Janssen Pharmaceutica Nv | Dosages pour détecter la neurodégénérescence |
| WO2020223279A1 (en) * | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| EP4232472A1 (en) * | 2020-10-26 | 2023-08-30 | JANSSEN Pharmaceutica NV | Method of safe administration of anti-tau antibody |
-
2021
- 2021-10-25 WO PCT/EP2021/079543 patent/WO2022090158A1/en not_active Ceased
- 2021-10-25 AU AU2021367878A patent/AU2021367878A1/en active Pending
- 2021-10-25 MX MX2023004831A patent/MX2023004831A/es unknown
- 2021-10-25 IL IL302386A patent/IL302386A/en unknown
- 2021-10-25 EP EP21798703.1A patent/EP4232155A1/en active Pending
- 2021-10-25 JP JP2023525044A patent/JP2023546504A/ja active Pending
- 2021-10-25 TW TW110139444A patent/TW202233666A/zh unknown
- 2021-10-25 US US17/509,889 patent/US20220127345A1/en active Pending
- 2021-10-25 CN CN202180087530.2A patent/CN116916955A/zh active Pending
- 2021-10-25 CA CA3199806A patent/CA3199806A1/en active Pending
- 2021-10-25 KR KR1020237017869A patent/KR20230093499A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004831A (es) | 2023-07-12 |
| TW202233666A (zh) | 2022-09-01 |
| US20220127345A1 (en) | 2022-04-28 |
| KR20230093499A (ko) | 2023-06-27 |
| CA3199806A1 (en) | 2022-05-05 |
| AU2021367878A1 (en) | 2023-06-22 |
| JP2023546504A (ja) | 2023-11-02 |
| EP4232155A1 (en) | 2023-08-30 |
| WO2022090158A1 (en) | 2022-05-05 |
| CN116916955A (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3143811A1 (en) | Anti-tau antibody and use of same | |
| IL323583A (en) | Methods for treating and preventing Alzheimer's disease | |
| KR20020089359A (ko) | Ａβ 펩티드를 격리시키는 인간화 항체 | |
| IL272321B1 (en) | Methods and compositions for treating amyloid deposition diseases | |
| IL272361B1 (en) | Antibodies that bind active alpha-synuclein | |
| IL302386A (en) | Methods of reducing tau in human subjects | |
| IL302383A (en) | Method of safe administration of anti-tau antibody | |
| IL300059A (en) | Anti-Abata antibodies | |
| IL318087A (en) | Antibody against human TRL7 | |
| JP2023548005A (ja) | 抗トランスサイレチン抗体およびその使用方法 | |
| KR20250107906A (ko) | 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도 | |
| JP2024547001A (ja) | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 | |
| JP2024532438A (ja) | 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法 | |
| WO2014160133A2 (en) | Anti-(+) --methamphetamine monoclonal antibodies | |
| IL322281A (en) | Methods for treating neurological disorders with anti-Abeta antibodies | |
| Class et al. | Patent application title: Methods of Reducing Tau in Human Subjects | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| EA052839B1 (ru) | Способы снижения уровня тау-белка у человеческих индивидов | |
| HK40100364A (zh) | 减少人类受试者中的tau的方法 | |
| EA050381B1 (ru) | Способы снижения уровня тау-белка у человеческих индивидов | |
| JP7685766B2 (ja) | 抗ｉｄｅ抗体およびその使用 | |
| IL296579A (en) | Antibody against ccl24 for use in a treatment method | |
| EA051320B1 (ru) | Способ безопасного введения антитела к тау-белку |